Two new closely related rat models with relevance to arterial thrombosis - Efficacies of different antithrombotic drugs

Thrombosis and Haemostasis

Volumn 77, Issue 1, 1997, Pages 183-189

  Vogel, Gerard M T ^a   Van Amsterdam, Ronald G M ^a   Zandberg, Pieter ^a   Van Houwelingen, Piet ^a   Kop, Wim J ^a   Van Mensvoort, Frans W J ^a   Meuleman, Dirk G ^a  

^a NV ORGANON   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A; CLOPIDOGREL; DANAPAROID; ENOXAPARIN; FONDAPARINUX; GLYCOSAMINOGLYCAN; MILRINONE; NADROPARIN; THROMBIN INHIBITOR; THROMBOCYTE ACTIVATING FACTOR DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA; ARTERY BLOOD FLOW; ARTERY THROMBOSIS; ARTICLE; CAVA VEIN; CONTROLLED STUDY; DOSE RESPONSE; FIBRIN DEPOSITION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; VEIN BLOOD FLOW;

EID: 0031058620     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1655928     Document Type: Article

References (35)

1. Fuster V, Stein B, Ambrose JA, Badimon L, Badimon JJ, Chesebro JH. Atherosclerotic plaque rupture and thrombosis. Evolving concepts. Circulation 1990; 82 (suppl II: 47-59).
2. Freiman DG. The structure of thrombi. In: Hemostasis and Thrombosis. Basic Principles and Clinical Practice. Colman RW, Hirsh J, Marder VJ, Salzman EW, eds. J. B. Lippincott Company, Philadelphia, PA 1982; pp. 767.
3. Meuleman DG, Hobbelen PMJ, van Dedem G, Moelker HCT. A novel anti-thrombotic heparinoid (Org 10172) devoid of bleeding inducing capacity: A survey of its pharmacological properties in experimental animal models. Thromb Res 1982; 27: 353-63.
4. Vogel GMT, Meuleman DG, Bourgondiën FGM, Hobbelen PMJ. Comparison of two experimental thrombosis models in rats. Effects of four glycosaminoglycans. Thromb Res 1989; 54: 399-410.
5. Hobbelen PMJ, van Dinther TG, Vogel GMT, van Boeckel CAA, Moelker HCT, Meuleman DG. Pharmacological profile of the chemically synthesized antithrombin III binding fragment of heparin (pentasaccharide) in rats. Thromb Haemost 1990; 63: 265-70.
6. Rudall, KM. Comparative biology and biochemistry of collagen. In: "Treatise on collagen" part A, chapter 2. Gould BS, ed. Academic Press Inc, LTD London 1968; 83-135.
7. Meuleman DG, Vogel GMT, Van Delft AML. Effects of intra-arterial cannulation on blood platelet consumption in rats. Thromb Res 1980; 20: 45-55.
8. Marchalonis, J. An enzymatic method for the trace iodination of immunoglobulins and other proteins. Biochem J 1969; 113: 299-305.
9. Meuleman DG, Vogel GMT, Stulemeyer SM, Moelker HCT. Analysis of platelet survival curves in an arterial thrombosis model in rats. Thromb Res 1980; 20: 31-43.
10. Degryse E, Acker M, Defreyn G, Bernat A, Maffrand JP, Roitsch C, Courtney M. Point mutations modifying the thrombin inhibition kinetics and antithrombotic activity in vivo of recombinant hirudin. Protein Engineering 1989; 2: 459-65.
11. Bowman WC, Rand MJ. Textbook of pharmacology. Blackwell Scientific Publications, second edition, pp 41.37-41.43.
12. Baier RE, Loeb GI, Wallace GT. Role of an artificial boundary in modifying blood proteins. Fed Proc 1971; 30: 1523-38.
13. Lyman DJ, Metcalf LC, Albo D Jr, Richards KF, Lamb J. The effect of chemical structure and surface properties of synthetic polymers on the coagulation of blood. III. In vivo adsorption of proteins on polymer surfaces. Transactions of the American Society for Artificial Internal Organs 1974; 20: 474-8.
14. Griffin JH, Cochrane CG. Recent advances in the understanding of contact activation reactions. Semin Thromb Haemost 1979; 5: 254-73.
15. Salzman EW, Lindon J, McManama G, Ware JA. Role of fibrinogen in activation of platelets by artificial surfaces. Ann NY Acad Sci 1987; 516: 184-95.
16. Baumgartner HR, Muggli R, Tschopp TB, Turitto VT. Platelet adhesion, release and aggregation in flowing blood: effects of surface properties and platelet function. Thromb Haemost 1976; 35: 124-38.
17. Walsh PN. Platelet-coagulant protein interactions. In: Hemostasis and Thrombosis. Basic Principles and Clinical Practice. Colman RW, Hirsh J, Marder VJ, Salzman EW, eds. J.B. Lippincott Company, Philadelphia, PA 1982; pp. 404-20.
18. Needleman S, Hook JC. Platelets and leukocytes. In: Hemostasis and Thrombosis. Basic Principles and Clinical Practice. Colman RW, Hirsh J, Marder VJ, Salzman EW, eds. J.B. Lippincott Company, Philadelphia, PA 1982; pp. 716-25.
19. Packham MA. The behavior of platelets at foreign surfaces. Proc Soc Exp Biol Med 1988; 189: 261-74.
20. Hollenbach S, Sinha U, Lin PH, Needham K, Frey L, Hancock T, Wong A, Wolf D. A comparative study of prothrombinase and thrombin inhibitors in a novel rabbit model of non-occlusive deep vein thrombosis. Thromb Haemost 1994; 71: 357-62.
21. Lüscher TF, Diederich D, Siebenmann R, Lehmann K, Stulz P, von Segesser L, Yang Z, Turino M, Grädel E, Weber E, Bühler FR. Different endothelium-dependent relaxations in arterial and venous coronary bypass grafts. N Engl J Med 1988; 319: 462-7.
22. Subramanian VA, Hernandez Y, Tack-Goldman K, Grabowski EF, Weksler BB. Prostacyclin production by internal mammary artery as a factor in coronary artery bypass grafts. Surgery 1986; 100: 376-83.
23. Merino A, Cohen M, Badimon JJ, Fuster V, Badimon L. Synergistic action of severe wall injury and shear forces on thrombus formation in arterial stenosis: Definition of a thrombotic shear rate threshold. J Am Coll Cardiol 1994; 24: 1091-4.
24. Roald HE, Barstad RM, Kierulf P, Skjørten F, Dickinson JP, Kieffer G, Sakariassen KS. Clopidogrel - a platelet inhibitor which inhibits thrombogenesis in non-anticoagulated human blood independently of the blood flow conditions. Thromb Haemost 1994; 71: 655-62.
25. Yao SK, Ober JC, Ferguson JJ, Maffrand JP, Anderson HV, Buja LM, Willerson JT. Clopidogrel is more effective than aspirin as adjuvant treatment to prevent reocclusion after thrombolysis. Am J Physiol 1994; 267: H488-H93.
26. Lane DA, Denton J, Flynn AM, Thunberg L, Lindahl U. Anticoagulant activities of heparin oligosaccharides and their neutralization by platelet factor 4. Biochem J 1984; 218: 725-32.
27. Eitzman DT, Chi L, Saggin L, Schwartz RS, Lucchesi BR, Fay WP. Heparin neutralization by platelet-rich thrombi. Role of platelet factor 4. Circulation 1994; 89: 1523-9.
28. Hemker HC. Thrombin generation, an essential step in haemostasis and thrombosis. In: Haemostasis and Thrombosis. Bloom AL, Forbes CD, Thomas DP, Tuddenham EGD, eds. 1994; 477-90.
29. Béguin S, Choay J, Hemker HC. The action of a synthetic pentasaccharide on thrombin generation in whole plasma. Thromb Haemost 1989; 61: 397-401.
30. Vogel GMT, van Amsterdam RGM, Kop WJ, Meuleman DG. Pentasaccharide and Orgaran arrest, whereas heparin delays thrombus formation in a rat arteriovenous shunt. Thromb Haemost 1993; 69: 29-34.
31. Salzman EW, Rosenberg RD, Smith MH, Lindon JN, Favreau L. Effect of heparin and heparin fractions on platelet aggregation. J Clin Invest 1980; 65: 64-73.
32. Umetsu T, Sanai K. Effect of 1-methyl-2-mercapto-5-(3-pyridyl) imidazole (KC-6141), an anti-aggregating compound, on experimental thrombosis in rats. Thromb Haemost 1978; 39: 74-83.
33. Shand RA, Smith JR, Wallis RB. Expression of the platelet procoagulant activity in vivo in thrombus formation in an extra-corporeal shunt in the rat. Thromb Res 1984; 36: 223-32.
34. Hladovec J. Experimental arterial thrombosis in rats with continuous registration. Thromb Diath Heamorrh 1973; 29: 407-10.
35. Kurz KD, Main BW, Sandusky GE. Rat model of arterial thrombosis induced by ferric chloride. Thromb Res 1990; 60: 269-80.